Implementation of Teledermoscopy and Artificial Intelligence

Brief summary (registry, in English)

The study has 2 parts. Part 1 will investigate the effects of introducing teledermoscopy in clinical practice, more specifically the change in referral patterns, the risk of undetected skin cancers and the effect on diagnostic accuracy in general practitioners. Part 2 will create artificial intelligence (AI) as support tools for teledermocsopic assessors and investigate the effect of introducing AI within teledermocsopy. In this study the investigators will measure the diagnostic accuracy of teledermoscopic assessors that had access to the results of artificial intelligence algorithm compared to those who did not. Data will be collected through teledermoscopic referrals, patient records, national registries and questionnairs.

What you commit to

• Study type: Observational
• Planned participants: 8000
• From 16 Aug 2021 to the primary completion date, 31 Aug 2029
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 15 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.